BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24959336)

  • 1. Immunological deregulation in classic hodgkin lymphoma.
    Romano A; Vetro C; Caocci G; Greco M; Parrinello NL; Di Raimondo F; La Nasa G
    Mediterr J Hematol Infect Dis; 2014; 6(1):e2014039. PubMed ID: 24959336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.
    Chiu J; Ernst DM; Keating A
    Front Immunol; 2018; 9():267. PubMed ID: 29491867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.
    La Nasa G; Greco M; Littera R; Oppi S; Celeghini I; Caria R; Lai S; Porcella R; Martino M; Romano A; Di Raimondo F; Gallamini A; Carcassi C; Caocci G
    J Hematol Oncol; 2016 Mar; 9():26. PubMed ID: 26983546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.
    Georgoulis V; Papoudou-Bai A; Makis A; Kanavaros P; Hatzimichael E
    Biology (Basel); 2023 Jun; 12(6):. PubMed ID: 37372147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.
    Kezlarian B; Alhyari M; Venkataraman G; Karner K; Inamdar KV; Menon MP
    Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):180-184. PubMed ID: 28877074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard therapies versus novel therapies in Hodgkin lymphoma.
    Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
    Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.
    Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Maira-Gonzalez N; Garcia-Rojo M
    Front Oncol; 2022; 12():1000762. PubMed ID: 36338756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma.
    Guan H; Xie L; Leithäuser F; Flossbach L; Möller P; Wirth T; Ushmorov A
    Blood; 2010 Sep; 116(9):1469-78. PubMed ID: 20519630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients.
    Amini RM; Enblad G; Hollander P; Laszlo S; Eriksson E; Ayoola Gustafsson K; Loskog A; Thörn I
    BMC Cancer; 2019 Apr; 19(1):316. PubMed ID: 30953461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features.
    El Hussein S; Fang H; Jelloul FZ; Wang W; Loghavi S; Miranda RN; Friedberg JW; Burack WR; Evans AG; Xu J; Medeiros LJ
    Arch Pathol Lab Med; 2023 Dec; ():. PubMed ID: 38059511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment.
    Ferrarini I; Rigo A; Visco C; Krampera M; Vinante F
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33327433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
    Tian X; Xu J; Dorfman DM
    Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic Hodgkin Lymphoma - Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers.
    Perry AM; Smith LB; Bagg A
    Acta Med Acad; 2021 Apr; 50(1):110-125. PubMed ID: 34075767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immune dysregulation in MPN.
    Barosi G
    Curr Hematol Malig Rep; 2014 Dec; 9(4):331-9. PubMed ID: 25139710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell-derived Hodgkin lymphoma has motility characteristics intermediate between Hodgkin and anaplastic large cell lymphoma.
    Bein J; Flinner N; Häupl B; Mathur A; Schneider O; Abu-Ayyad M; Hansmann ML; Piel M; Oellerich T; Hartmann S
    J Cell Mol Med; 2022 Jun; 26(12):3495-3505. PubMed ID: 35586951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic approach for classic Hodgkin lymphoma in small samples with an emphasis on PD-L1 expression and EBV harboring in tumor cells: a brief review from morphology to biology.
    Takahara T; Sakakibara A; Tsuyuki Y; Satou A; Kato S; Nakamura S
    J Clin Exp Hematop; 2023; 63(2):58-64. PubMed ID: 37380470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histology of pediatric classic Hodgkin lymphoma: From diagnosis to prognostic stratification.
    Pizzi M; Tazzoli S; Carraro E; Chaviano F; Massano D; Lovisa F; Mussolin L; Todesco A; Biffi A; d'Amore ES; Pillon M; Rugge M
    Pediatr Blood Cancer; 2020 May; 67(5):e28230. PubMed ID: 32134194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging.
    Lyapichev KA; You MJ; Vega F; Solis LM; Medeiros LJ
    Virchows Arch; 2020 Sep; 477(3):437-444. PubMed ID: 32152665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies.
    Boot MV; Schaapveld M; Van den Broek EC; Hijmering NJ; Group P; Van der Oord K; Van Leeuwen FE; Dinmohamed AG; Koens L; De Jong D
    Haematologica; 2023 May; 108(5):1349-1358. PubMed ID: 36263842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma.
    Menéndez V; Solórzano JL; García-Cosío M; Alonso-Alonso R; Rodríguez M; Cereceda L; Fernández S; Díaz E; Montalbán C; Estévez M; Piris MA; García JF
    Sci Rep; 2024 Jan; 14(1):710. PubMed ID: 38184757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.